Lundbeck hopes long-term Covid-19 effects will boost Trintellix

In a new study by Canadian researchers, Lundbeck's antidepressant dug Trintellix will be tested as a treatment for the long-term cognitive effects of Covid-19.

Photo: PR / Lundbeck

Canadian scientist Roger McIntyre will spearhead a new clinical trial, including 200 participants, to investigate whether Lundbeck's drug Trintellix, which is normally used in depression treatment, can potentially treat Covid-19 long-term effects, reports Danish business daily Børsen.

The study is approved by the Danish pharmaceutical company Lundbeck, which has also decided to supply the trial with the medicine vortioxetine, sold under the brand name Trintellix.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs